Impact of birth weight at term on rates of emergency room visits and hospital admissions following vaccination at 2 months of age

Vaccine

Volumn 29, Issue 46, 2011, Pages 8267-8274

  Wilson, Kumanan ^a,b   Hawken, Steven ^a   Kwong, Jeffrey C ^b,c,d,e   Deeks, Shelley L ^c,d   Manuel, Doug G ^a,f   Henningsen, Kirsten Holdt ^a   Crowcroft, Natasha S ^c,d  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c PUBLIC HEALTH ONTARIO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF OTTAWA   (Canada)

Author keywords

2 month vaccination; Adverse events following immunization; Birth weight; Self controlled case series design

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE;

ARTICLE; BIRTH WEIGHT; CANADA; CASE STUDY; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; EMERGENCY ROOM VISIT; EMERGENCY WARD; HOSPITAL ADMISSION; HUMAN; INCIDENCE; INFANT; LOW BIRTH WEIGHT; PRIORITY JOURNAL; SMALL FOR DATE INFANT; VACCINATION;

BIRTH WEIGHT; EMERGENCY MEDICAL SERVICES; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; ONTARIO; RISK ASSESSMENT; VACCINATION;

EID: 80054031311     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.08.107     Document Type: Article

References (23)

1. Davis R.L., Rubanowice D., Shinefield H.R., Lewis N., Gu D., Black S.B., DeStefano F., et al. Immunization levels among premature and low-birth-weight infants and risk factors for delayed up-to-date immunization status. Centers for Disease Control and Prevention Vaccine Safety Datalink Group. JAMA: The Journal of the American Medical Association 1999, 282(6):547-553.
2. Conway S., James J., Balfour A., Smithells R. Immunisation of the preterm baby. The Journal of Infection 1993, 27(2):143-150.
3. Pullan C.R., Hull D. Routine immunisation of preterm infants. Archives of Disease in Childhood 1989, 64(10):1438-1441.
4. D'Angio C.T., Maniscalco W.M., Pichichero M.E. Immunologic response of extremely premature infants to tetanus, haemophilus influenzae, and polio immunizations. Pediatrics 1995, 96(1 Pt 1):18-22.
5. Saari T.N. Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 2003, 112(1 Pt 1):193-198.
6. Public Health Agency of Canada Canadian immunization guide. 7th ed. Part 3. Recommended immunization-immunization of infants born prematurely 2006.
7. Lau Y-L., Tam A.Y.C., Ng K.W., Tsoi N.S., Lam B., Lam P., et al. Response of preterm infants to hepatitis B vaccine. The Journal of Pediatrics 1992, 121(6):962-965.
8. Slack M.H., Schapira D., Thwaites R.J., Andrews N., Schapira D. Acellular pertussis vaccine given by accelerated schedule: response of preterm infants. Archives of Disease in Childhood. Fetal and Neonatal Edition 2004, 89(1):F57-F60.
9. Schloesser R.L., Fischer D., Otto W., Rettwitz-Volk W., Herden P., Zielen S. Safety and immunogenicity of an acellular pertussis vaccine in premature infants. Pediatrics 1999, 103(5):e60.
10. D'Angio C.T. Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability. Paediatric drugs 2007, 9(1):17-32.
11. Khalak R., Pichichero M.E., D'Angio C.T. Three-year follow-up of vaccine response in extremely preterm infants. Pediatrics 1998, 101(4 Pt 1):597-603.
12. Farrington P., Pugh S., Colville A., Flower A., Nash J., Morgan-Capner P., et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995, 345(8949):567-569.
13. Whitaker H.J., Farrington C.P., Spiessens B., Musonda P. Tutorial in biostatistics: the self-controlled case series method. Statistics in Medicine 2006, 25(10):1768-1797.
14. Siegrist C.A. Mechanisms underlying adverse reactions to vaccines. Journal of Comparative Pathology 2007, 137(Suppl. 1):S46-S50.
15. Wilson K., Hawken S., Potter B.K., Chakraborty P., Kwong J., Crowcroft N., et al. Patterns of emergency room visits, admissions and death following recommended pediatric vaccinations - a population based study of 969,519 vaccination events. Vaccine 2011, 29(21):3746-3752.
16. Xu S., Garguillo P., Mullooly J., McClure D., Hambridge S.J., Glanz J. Fitting parametric and semi-parametric conditional Poission regression models with Cox's partial likelihood in self-controlled case series and matched cohort studies. Journal of Data Science 2010, 8:349-360.
17. Linder N., Handsher R., German B., Sirota L., Bachman M., Zinger S., et al. Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth. Archives of Disease in Childhood. Fetal and Neonatal Edition 2000, 83(1):F24-F27.
18. Slack M.H., Schapira D., Thwaites R.J., Burrage M., Southern J., Andrews N., et al. Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis-Haemophilus influenzae type b conjugate vaccines. The Journal of Infectious Diseases 2001, 184(12):1617-1620.
19. Esposito S., Pugni L., Bosis S., Proto A., Cesati L., Bianchi C., et al. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 2005, 23(14):1703-1708.
20. Moore G.E., Guptill L.F., Ward M.P., Glickman N.W., Lewis H.B., et al. Adverse events diagnosed within three days of vaccine administration in dogs. Journal of the American Veterinary Medical Association 2005, 227(7):1102-1108.
21. Virtanen M., Peltola H., Paunio M., Heinonen O.P. Day-to-day reactogenicity and the healthy vaccine effect of measles-mumps-rubella vaccination. Pediatrics 2000, 106(5):E62.
22. Fine P.E., Chen R.T. Confounding in studies of adverse reactions to vaccines. American Journal of Epidemiology 1992, 136(2):121-135.
23. Davis R.L., Marcuse E., Black S., Shinefield H., Givens B., Schwalbe J., et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics 1997, 100(5):767-771.